TrialNature medicine2023

Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.

John M Kirkwood et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.